Literature DB >> 1855979

Role of lipooligosaccharides in experimental dermal lesions caused by Haemophilus ducreyi.

A A Campagnari1, L M Wild, G E Griffiths, R J Karalus, M A Wirth, S M Spinola.   

Abstract

The mouse and rabbit intradermal injection models have been used to define factors that may be important in Haemophilus ducreyi pathogenesis. We used H. ducreyi strains with diverse geographic origins and phenotypic characteristics to evaluate the experimental models. Injection of live and heat-killed bacteria caused skin abscesses in both models. Semiquantitative cultures of skin injected with live bacteria showed that H. ducreyi failed to replicate in animal tissue. These data suggested that the experimental lesions were caused by a heat-stable substance such as lipooligosaccharide (LOS). In mice, injection of H. ducreyi and Haemophilus influenzae LOS and Escherichia coli lipopolysaccharide caused mild to moderate inflammation. In rabbits, injection of H. ducreyi LOS caused intradermal abscesses that were histologically similar to those caused by live and heat-killed bacteria. H. ducreyi and Neisseria gonorrhoeae LOS caused significantly larger lesions than equivalent amounts of H. influenzae LOS and E. coli lipopolysaccharide in the rabbit model. We conclude that the intradermal injection models are not valid models to study the growth of H. ducreyi in vivo. However, these data indicate that H. ducreyi LOS may play an important role in the pathogenesis of chancroid and that the rabbit model should be useful in studying H. ducreyi LOS toxicity at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855979      PMCID: PMC258062          DOI: 10.1128/iai.59.8.2601-2608.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Studies on Chancroid: I. Observations on the Histology with an Evaluation of Biopsy as a Diagnostic Procedure.

Authors:  W H Sheldon; A Heyman
Journal:  Am J Pathol       Date:  1946-03       Impact factor: 4.307

2.  Antimicrobial susceptibility of Haemophilus ducreyi.

Authors:  G W Hammond; C J Lian; J C Wilt; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

3.  Characterization of skin lesions in mice following intradermal inoculation of Haemophilus ducreyi.

Authors:  M Tuffrey; F Alexander; R C Ballard; D Taylor-Robinson
Journal:  J Exp Pathol (Oxford)       Date:  1990-04

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Comparative studies on the toxicity of Escherichia coli lipopolysaccharide endotoxin in various animal species.

Authors:  I Berczi; L Bertók; T Bereznai
Journal:  Can J Microbiol       Date:  1966-10       Impact factor: 2.419

6.  A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels.

Authors:  C M Tsai; C E Frasch
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

7.  Histological aspects of sexually transmitted genital lesions.

Authors:  A L Freinkel
Journal:  Histopathology       Date:  1987-08       Impact factor: 5.087

8.  Electrophoretic heterogeneity and interstrain variation of the lipopolysaccharide of Haemophilus influenzae.

Authors:  T J Inzana
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

9.  Virulence factors of Haemophilus ducreyi.

Authors:  J A Odumeru; G M Wiseman; A R Ronald
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

10.  Toxic activity of purified lipopolysaccharide of Neisseria gonorrhoeae for human fallopian tube mucosa.

Authors:  C R Gregg; M A Melly; C G Hellerqvist; J G Coniglio; Z A McGee
Journal:  J Infect Dis       Date:  1981-03       Impact factor: 5.226

View more
  58 in total

Review 1.  Immunopathogenesis of Haemophilus ducreyi infection (chancroid).

Authors:  Stanley M Spinola; Margaret E Bauer; Robert S Munson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  The LspB protein is involved in the secretion of the LspA1 and LspA2 proteins by Haemophilus ducreyi.

Authors:  Christine K Ward; Jason R Mock; Eric J Hansen
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

3.  Haemophilus ducreyi inhibits phagocytosis by U-937 cells, a human macrophage-like cell line.

Authors:  G E Wood; S M Dutro; P A Totten
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  The cytolethal distending toxin from the chancroid bacterium Haemophilus ducreyi induces cell-cycle arrest in the G2 phase.

Authors:  X Cortes-Bratti; E Chaves-Olarte; T Lagergård; M Thelestam
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

5.  Involvement of the Haemophilus ducreyi gmhA gene product in lipooligosaccharide expression and virulence.

Authors:  B A Bauer; M K Stevens; E J Hansen
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Use of pyocin to select a Haemophilus ducreyi variant defective in lipooligosaccharide biosynthesis.

Authors:  A A Campagnari; R Karalus; M Apicella; W Melaugh; A J Lesse; B W Gibson
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  Characterization of the hemolytic activity of Haemophilus ducreyi.

Authors:  P A Totten; D V Norn; W E Stamm
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  Haemophilus ducreyi attaches to and invades human epithelial cells in vitro.

Authors:  P A Totten; J C Lara; D V Norn; W E Stamm
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Identification and characterization of the N-acetylglucosamine glycosyltransferase gene of Haemophilus ducreyi.

Authors:  Shuhua Sun; N Karoline Scheffler; Bradford W Gibson; Jing Wang; Robert S Munson
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Molecular analysis of the Haemophilus ducreyi groE heat shock operon.

Authors:  L M Parsons; A L Waring; M Shayegani
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.